Acumen Pharmaceuticals Pursues $125 Million IPO (Pending:ABOS)

Acumen Pharmaceuticals has filed preliminary conditions for a $125 million initial public offering. The company is working on an Alzheimer’s disease treatment. Here’s a look at my stock analysis./nRead More